Next Case Study

InSilicoVaccine – Tuberculosis

Augmenting Tuberculosis clinical trials with a Synthetic Arm


Tuberculosis is a contagious bacterial infection primarily caused by Mycobacterium tuberculosis. It affects the lungs but can also affect other parts of the body. Tuberculosis remains a significant global health concern, necessitating ongoing research and clinical trials to develop effective treatments and vaccines, such as the polyantigenic, liposomized vaccine RUTI®

Question of Interest

How does the design of the RUTI® vaccine, characterized by its polyantigenic and liposomized features, impact its effectiveness in combating tuberculosis?


AGENT-BASED MODEL: Dynamic simulations

Virtual patient population Immune System and Tuberculosis disease trajectory – Virtual tuberculosis patient population simulation of tuberculosis disease progression, mono- and combination therapy.


In silico trails of mono- or combination therapy for tuberculosis – Response to isoniazid and/or RUTI®️ treatment of the digital patients’ populations    


  • By using in silico methods to predict potential adverse effects of vaccines before they are tested in humans, researchers can identify and address safety concerns earlier in the development process. This could help minimize the risk of adverse events and increase public confidence in vaccines.
  • In silico methods can also be used to optimize vaccine design by predicting the most effective antigen sequences or adjuvants to elicit a robust immune response. This could help improve the efficacy of vaccines and reduce the risk of viral mutations.

Related Case Studies

In silico QSTR Model

In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.

Read More »

Fill the details to download the case study

Download your case study by clicking the link below